Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.55 |
| ▸ | MST1R | Q04912 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425059 | 0.95 | MET (0.51) | METMST1RNMT1CYP3A4 | |
| SCHEMBL2424668 | 0.93 | MET (0.48) | METMST1RNMT1CYP3A4 | |
| SCHEMBL2419752 | 0.91 | MET (0.47) | METMST1RNMT1CYP3A4 | |
| SCHEMBL2427023 | 0.89 | MET (0.56) | METMST1RCYP3A4 | |
| SCHEMBL2424917 | 0.84 | MET (0.52) | METMST1RCYP3A4 | |
| SCHEMBL2424781 | 0.84 | MET (0.69) | METMST1R | |
| SCHEMBL2421977 | 0.83 | MET (0.48) | METMST1RCYP3A4 | |
| SCHEMBL2422550 | 0.82 | MET (0.66) | METMST1RCYP3A4 | |
| SCHEMBL2425057 | 0.82 | MET (0.62) | METMST1R | |
| SCHEMBL2425895 | 0.81 | MET (0.48) | METMST1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265616-B1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI PHARM INC (US) | 2013-11-20 | — | — | EP | claimed |
| US-8022206-B2 | Furo[3,2-C]pyridines | OSI Pharmaceuticals, LLC (US) | 2011-09-20 | — | — | US | claimed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | claimed |
| EP-2265616-B1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI PHARM INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8022206-B2 | Furo[3,2-C]pyridines | OSI Pharmaceuticals, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | RET, MET, ERBB2 | MET 2/4885MST1R 104/4885NMT1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.